Severe Asthma Patient Outcomes by Inflammatory Phenotype

Patrizia Pignatti's 2026 study analyzes 113 severe asthma patients receiving biologic therapy. The research stratifies patients by baseline inflammatory patterns and tracks clinical outcomes over 6 and 12 months. It examines biomarkers, lung function, and symptom scores to assess phenotype-dependent treatment efficacy.

Use Cases

• Predict treatment response in neutrophilic vs. eosinophilic phenotypes using baseline biomarkers like FeNO and blood eosinophil counts.
• Analyze correlations between inflammatory patterns and comorbidities such as obstructive sleep apnea or chronic rhinosinusitis.
• Model changes in lung function metrics like Forced Vital Capacity (FVC) over a 12-month follow-up period.
• Assess reductions in exacerbation rate and symptom burden scores (ACQ-6, ACT) post-biologic therapy initiation.

Strengths

• Includes data for 113 severe asthma patients with detailed clinical follow-up.
• Tracks multiple outcome measures: lung function, biomarker levels, exacerbation rates, and symptom scores over 6 and 12 months.

Limitations

• Small cohort size, with only 103 patients analyzed after excluding 10 paucigranulocytic cases.
• Retrospective observational study design limits causal inference.
• Data is presented in a static PDF report (229.6 KB), not a structured data file, limiting direct analysis.

Provenance

Source

figshare, authored by Patrizia Pignatti.

Collection Method

Retrospective observational study of patients with severe asthma at a clinical site.

Time Range

Follow-up period of 6 and 12 months after initiation of biologic therapy.

Freshness

Study data last updated in April 2026.

Geography

null